Cross-Sector entity
All 1 tracked stories fall under one category: pharma. Akoya is most often covered alongside Centers for Medicare & Medicaid Services, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Cross-Sector story that mention Akoya, all published on March 4, 2026.
1 verified story tracked
Last mentioned: Mar 4, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Akoya is most often covered alongside Centers for Medicare & Medicaid Services, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Cross-Sector story that mention Akoya, all published on March 4, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Akoya. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Company reports 25% total revenue growth and progress in clinical diagnostic pivot.
FDA 510(k) Submission
Premarket notification submitted for Lucent AD Complete diagnostic test.
CMS Reimbursement Milestone
CMS approves $897 reimbursement rate for Lucent AD Complete, establishing a national reference price.
Assay Portfolio Expansion
Launch of 13 new assays including pTau-205 and pTau-212 for neurodegenerative research.
Quanterix reported Q4 2025 revenue of $43.9 million, driven by a 25% year-over-year increase and significant progress in its Alzheimer’s diagnostic portfolio. Despite organic declines in its core Simoa and Spatial segments, the company secured a $897 CMS reimbursement rate for its Lucent AD Complete test and submitted its 510(k) to the FDA.
